# FORAGER-2 (NCT07218380)

> A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

No report yet. It can be ordered.

- Drugs tested: vepugratinib plus enfortumab vedotin plus pembrolizumab

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07218380
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Eli Lilly and Company
- Conditions: Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Neoplasm Metastasis
- Interventions: Vepugratinib; Placebo; EV; Pembrolizumab
- Enrollment: 450
- Primary outcome: Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab
- Primary outcome: Safety Lead-in: Overall Response Rate (ORR)
- Primary outcome: Progression-free Survival (PFS)

## Indexed commentary on FORAGER-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 14 posts on X
- 3 videos on X
- 2 podcast episodes
- 1 YouTube video

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=forager-2-nct07218380

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07218380", "email": "<work email>"}; the inbox owner confirms by the emailed link.